Histoplasmosis News and Research

RSS

Histoplasmosis is an infectious condition caused by the fungus Histoplasma capsulatum. It is caused when the spores of the fungus are inhaled into the lungs. The lungs are the primary infection site.

How did the COVID-19 pandemic impact the fungal infection hospitalization rates?

Researchers examined hospitalizations for fungal infections during the coronavirus disease 2019.

9 Jun 2023

Experts highlight the expanding presence and emerging risks from three endemic fungal diseases

Infectious diseases expert George Thompson has been studying and treating fungal diseases for over two decades. He monitors their spread, symptoms and relative risks.

22 Nov 2022

Increased distribution of fungal infections throughout the U.S.

Researchers update the geographic distribution of these species throughout the U.S.

21 Nov 2022

Scientists find evidence of fungal organism Histoplasma capsulatum in Antarctica

...

20 Sep 2022

False positive monkeypox tests in low-risk patients with no exposures

Researchers reported three monkeypox diagnoses presenting atypical rashes.

13 Sep 2022

Study reveals infections by Histoplasma fungus as major cause of death in people with HIV

A series of autopsies performed in an infectious disease hospital in the Brazilian Amazon reveals that infections by the Histoplasma fungus are a major cause of death in people with HIV.

1 Jun 2021

Rare pulmonary disease discovered in rural Alberta

A rare pulmonary disease that is linked to bats has made Alberta home, according to new research led by provincial lab scientists.

19 Mar 2021

ATS publishes clinical guideline on laboratory diagnosis of fungal infections

The American Thoracic Society has published an official clinical guideline on laboratory diagnosis of fungal infections in pulmonary and critical care medicine in the Society's Aug. 30 American Journal of Respiratory and Critical Care Medicine.

30 Aug 2019

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

28 Mar 2019

Using a health information exchange network to enhance disease surveillance

How do public health officials know if there is a disease outbreak and where that outbreak has occurred?

12 Feb 2019

Which animal is most likely to spread the latest plague?

There are a large number of infections that are borne and carried by animals and spread to humans. These are called zoonotic diseases wherein the microbe or pathogen jumps from one species of the animals to another. Now a new study has ranked mammals based on the risk they pose to humans in terms of spreading infectious diseases to humans.

22 Jun 2017

Despite availability of life-saving medicaiton, annual deaths due to fungal meningitis are still over 180,000

International HIV experts have reported approximately 250,000 fungal meningitis cases annually, in the AIDS report, sub-Saharan Africa contributing 73% of cases. Cryptococcus fungus causes fungal meningitis and usually affects individuals who are above 35 years old, affecting the tissues covering the brain and the spinal cord

8 May 2017

Recent estimates reveal burden of serious fungal diseases in 14 different countries

Estimates never before attempted, show the number of people affected by serious fungal diseases in 14 of the worst affected countries across the globe have just been published.

22 Feb 2017

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

6 Apr 2016

New diagnostic criteria can help distinguish malignant cancerous chest cavity masses from histoplasmosis

Researchers led by St. Jude Children's Research Hospital scientists have developed new diagnostic criteria to enable clinicians to distinguish malignant cancerous chest cavity masses from those caused by fungal histoplasmosis infection.

23 Jul 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.

10 Jun 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

New device may help collect bed bugs safely and effectively

In recent years, bed bugs (Cimex lectularius) have been appearing more and more often in beds around the world, and entomologists need specimens for research purposes.

14 May 2015